Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy
Recruiting · NCT06660355 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy | Bronchiolitis Obliterans, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cryptogenic organizing pneumonia, graft versus host disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-08-05 | NCT06660355 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
| Incyte Corporation | 153 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | United States | 259 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Univ of Miami - Sylvester Comprehensive Cancer Center | Miami | United States | 2 |
| University of Kansas Cancer Center | Kansas City | United States | 242 |
| University of Virginia Comprehensive Cancer Center | Charlottesville | United States | 7 |
| Virginia Commonwealth University | Richmond | United States | 38 |